Prestige BioPharma Limited (KRX:950210)
South Korea flag South Korea · Delayed Price · Currency is KRW
12,040
+910 (8.18%)
Last updated: Jun 27, 2025

Prestige BioPharma Ratios and Metrics

Millions KRW. Fiscal year is Jul - Jun.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Jun '25 Jun '24 Jun '23 Jun '22 Jun '21 Jun '20 2019
Market Capitalization
143,630103,966113,582137,620396,635-
Upgrade
Market Cap Growth
55.01%-8.47%-17.47%-65.30%--
Upgrade
Enterprise Value
177,14444,042-6,736-150,494-63,944-
Upgrade
Last Close Price
11950.008650.009450.0011450.0033000.00-
Upgrade
PE Ratio
33.03-6.47---
Upgrade
Forward PE
-12.0112.0112.01--
Upgrade
PS Ratio
16.58150.88701.81---
Upgrade
PB Ratio
0.270.200.210.320.69-
Upgrade
P/TBV Ratio
0.360.260.280.320.69-
Upgrade
EV/Sales Ratio
20.4563.92----
Upgrade
Debt / Equity Ratio
0.270.200.210.010.010.02
Upgrade
Debt / EBITDA Ratio
--9.11---
Upgrade
Asset Turnover
0.010.000---
Upgrade
Inventory Turnover
0.080.100.01---
Upgrade
Quick Ratio
1.231.572.247.2632.705.71
Upgrade
Current Ratio
1.381.722.317.4632.745.88
Upgrade
Return on Equity (ROE)
0.04%-10.38%-0.59%-42.08%-2.07%-15.29%
Upgrade
Return on Assets (ROA)
-5.17%-5.35%0.10%-13.89%-3.01%-6.12%
Upgrade
Return on Capital (ROIC)
-5.90%-6.07%0.12%-15.08%-3.18%-7.41%
Upgrade
Return on Capital Employed (ROCE)
--0.20%---
Upgrade
Earnings Yield
15.17%-31.66%15.47%-153.65%-1.86%-
Upgrade
FCF Yield
-68.90%-65.49%-95.65%-74.36%-4.13%-
Upgrade
Buyback Yield / Dilution
-0.07%---16.46%-20.98%-7.27%
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.